• Explore /
  • Poster
  • / Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).

Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).

Abstract Poster

Authors

null

Yemarshet Kelemework Gebreyohannes

Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium

Yemarshet Kelemework Gebreyohannes , Madelina-Elena Zhai , Agnieszka Wozniak , Jasmien Wellens , Jasmien Cornillie , Erica Evans , Alexandra K. Gardino , Nancy E. Kohl , Maria Debiec-Rychter , Raf Sciot , Patrick Schöffski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Citation

J Clin Oncol 34, 2016 (suppl; abstr 11030)

DOI

10.1200/JCO.2016.34.15_suppl.11030

Abstract #

11030

Poster Bd #

156

Abstract Disclosures

Similar Posters

First Author: Steven Bialick

First Author: Axel Le Cesne

Poster

2020 Gastrointestinal Cancers Symposium

Clinical activity of avapritinib in  ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).

Clinical activity of avapritinib in  ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).

First Author: Michael C. Heinrich

First Author: Michael C. Heinrich